In a recent article by Dr. William Makis, a renowned Nuclear Medicine Radiologist and Oncologist, the focus is on using Fenbendazole and Mebendazole for treating cancers, particularly aggressive forms like “turbo cancers” potentially linked to mRNA vaccines. Dr. Makis, a globally respected figure in oncology with over 100 peer-reviewed publications, advocates for these anti-parasitic drugs as promising cancer treatments. In his article, he highlights 10 new peer-reviewed studies from 2023 and 2024 that support the repurposing of these drugs for cancer treatment.
One key finding Dr. Makis points out is that the maximum therapeutic benefit of these drugs was achieved when combined with a ketogenic diet, emphasizing the importance of starving cancer cells of glucose. He outlines dosing protocols for various stages of cancer, recommending specific doses of Fenbendazole and Mebendazole depending on the patient’s cancer type, stage, and weight.
This article, part of Dr. Makis’ extensive body of work, showcases his deep expertise in cancer treatment, particularly in using repurposed drugs. His work has garnered widespread attention, including mentions on major platforms like Joe Rogan’s podcast. Dr. Makis continues to advocate for patient empowerment through knowledge, urging individuals to explore all available options, particularly when conventional treatments may not suffice.
Dr. Makis’ long-standing career includes over 11 years of experience as a Nuclear Medicine Oncologist at the Cross Cancer Institute and a faculty role at the University of Alberta. His research and dedication to integrating repurposed drugs into cancer care have made him one of the most followed oncologists in the world, with over 320,000 followers on social media. Through his work, he aims to offer patients a broader understanding of alternative cancer treatments and protocols. You can explore more of his insights and protocols on his popular Substack platform.
Dr. Makis’ groundbreaking research continues to inspire hope in patients worldwide by providing alternative treatment options that challenge conventional cancer care. As more studies unfold, Fenbendazole and Mebendazole may become more central to cancer care strategies.
